Publications

  1. Ahmadian A., Lin J., Neylan T., Woolley JD., O'Donovan A., Cohen B. Social integration and inflammation in individuals with and without posttraumatic stress disorder. Brain, Behavior, and Immunity. 2020

  2. Anderson B., Danforth A., Daroff R., Stauffer C., Ekman E., Agin-Liees G., Trope A., Boden M., Dilley J., Mitchell J., Woolley JD. Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study. EClinical Medicine. 2020

  3. Chuang B., Campellone T., Woolley JD. Oxytocin does not improve emotional prosody recognition in schizophrenia-spectrum disorders. Comprehensive Psychoneuroendocrinology. 2020

  4. Morrison T., De Coster L., Stauffer C., Wen J., Ahamadi E., Delucchi K., O'Donovan A., Woolley JD. Automatic Inhibition in Comorbid PTSD and Alcohol Use Disorder and Controls: an RCT of Intranasal Oxytocin. Psychoneuroendocrinology. In Press. 2020

  5. Stauffer CS, Moschetto JM, McKernan S, Meizner N, Chiang C, Rapier R, Hsiang E, Norona J, Borsari B, Woolley JD. Oxytocin-enhanced group therapy for methamphetamine use disorder: Randomized Controlled Trial. Journal of Substance Abuse Treatment. 2020

  6. Flanagan JC, Mitchell JM, Baker NL, Woolley J, Back SE, McQuaid JR, Neylan TC, Wolfe WR, & Brady KT (in press). Enhancing Prolonged Exposure Therapy for PTSD among Veterans with Oxytocin: Design of a Multisite Randomized Controlled Trial. Contemporary Clinical Trials.

  7. Abram SV, De Coster L, Roach BJ, Mueller BA, Van Erp TGM, Calhoun VD, Preda A, Lim KO, Tumor JA, Ford JM, Mathalon DH, Woolley DJ. Oxytocin Enhances an Amygdala Circuit Associated with Negative Symptoms in Schizophrenia: A Single-Dose, Placebo-Controlled, Crossover, Randomized Controlled Trial. Schizophrenia Bulletin, 46(3), 661-669. 

  8. Ahmadian AJ, Lin JE., Neylan TC, Woolley JD, O'Donovan A*, Cohen BE* (*Shared senior authorship). Social integration and inflammation in individuals with and without Posttraumatic Stress Disorder. Brain Behavior and Immunity. 2020

  9. Niles AN, Woolley J, Tripp P, Pesquita A, Vinogradov S, Neylan T, O'Donovan A. Randomized Controlled Trial Testing Mobile-based Attention Bias Modification for Posttraumatic Stress Disorder Using Personalized Word Stimuli. Clinical Psychological Science. 2020. [link]

  10. Marton T, Barnes DE, Wallace A, Woolley JD. Concurrent Use of Buprenorphine, Methadone, or Naltrexone Does Not Inhibit Ketamine's Antidepressant Activity. Biol Psychiatry. 2019;85(12):e75-e76. 

  11. Stauffer CS, Meizner NK, Morrison T, Wen J-H, Radanovich L, Leung D, Niles A, O'Donovan A, Batki SL, Woolley JD (2019), Effects of Oxytocin Administration on Cue-Induced Craving in Co-occuring Alcohol Use Disorder and PTSD: A Within-Participant Randomized Clinical Trial. Alcohol Clin Exp. [link]

  12. Trope A, Anderson B, Hooker A, Glick, G, Stauffer C, Woolley J (in press). Psychedelic-Assisted Group Therapy: A Systematic Review. Journal of Psychoactive Drugs. [link]

  13. Bradley ER, Brustkern J, De Coster L, van den Bos W, McClure SM, Seitz A, Woolley JD. (in press). Victory is its own reward: oxytocin increases costly competitive behavior in schizophrenia. Psychological Medicine. [link]

  14. Bradley ER, van Nieuwenhuizen A, Abram S, Niles AN, Woolley JD. Oxytocin does not improve working memory in schizophrenia. Schizophr Res. 2019 Jan 31. [link]

  15. De Coster L, Lin L, Mathalon D.H., Woolley JD. Neural and behavioral effects of oxytocin administration during theory of mind in schizophrenia and controls: a randomized control trial. Neuropsychopharmacol. 44, 1925-1931 (2019). 

  16. Stauffer CS, Moschetto JM, McKernan SM, Hsiang E, Borsari B, Woolley JD. Oxytocin-Enhanced Motivational Interviewing Group Therapy for Methamphetamine Use Disorder in Men Who Have Sex With Men: Study Protocol for a Randomized Controlled Trial. Trials. 2019;20:145. [link]

  17. Fulford, D., Treadway, M., Woolley, JD. Social Motivation in Schizophrenia: the Impact of Oxytocin on Vigor in the Context of Social and Non-Social Reinforcement. Journal of Abnormal Psychology. 2017.

  18. Human LJ, Woolley JD, Mendes WB. Effects of Oxytocin Administration on Receiving Help. Emotion. 2017 Nov 27. PMID: 29172621

  19. Burkner, P.C., Williams, D.R., Simmons, T.C., Woolley, JD. Intranasal oxytocin may improve high-level social cognition in Schizophrenia, but not social cognition or neurocognition in general: A multilevel Bayesian meta-analysis. The Journal of Psychoses and Related Disorders. 2017, Jun 06 [link]

  20. Bradley, ER., Woolley, JD. Oxytocin effects in schizophrenia: reconciling mixed findings and moving forward. Neuroscience & Biobehavioral Reviews. 2017 [link]

  21. Human, L. J., Thorson, K. R., Woolley, JD., Mendes, W. B. Combining oxytocin administration and positive emotion inductions: Examining social perception and analytical performance. Hormones and Behavior 90 (2017) 120-128 [pdf]

  22. Biagianti B, Fisher M, Howard L, Rowlands A, Vinogradov S, Woolley J. Feasibility and Preliminary Efficacy of Remotely Delivering Cognitive Training to People with Schizophrenia using Tablets. Schizophr Res Cogn. 2017 Dec; 10:7-14. PMID: 28824850. PMCID: PMC5544490

  23. Fisher M, Nahum M, Howard E, Rowlands A, Brandrett B, Kermott A, Woolley JD, Vinogradov S. Supplementing intensive targeted computerized cognitive training in schizophrenia with social cognitive exercises: an interim report. Psychiatric Rehabilitation Journal 40(1), 20-32. 2017.

  24. Stauffer, C. S., Dobberteen, L., & Woolley, JD (2016). American Alcohol Photo Stimuli (AAPS): A standardized set of alcohol and matched non-alcohol images. The American Journal of Drug and Alcohol Abuse, 1-9.  [link]

  25. Biagianti B, Schlosser D, Nahum M, Woolley J, Vinogradov S. Creating Live Interactions to Mitigate Barriers (CLIMB): A Mobile Intervention to Improve Social Functioning in People with Chronic Psychotic Disorders. JMIR Ment Health. 2016 Dec 13; 3(4):e52. PMID: 27965190. PMCID: PMC5192235

  26. Woolley JD, Chuang B, Fussel C, Scherer S, Biagianti B, Fulford D, Vinogradov S. Intranasal oxytocin increases facial expressivity in patients with schizophrenia and health controls. Psychological Medicine. 2016.

  27. Stauffer CS, Musinipally V, Suen A, Lynch K, Shapiro B, Woolley JD. A two-week pilot study of intranasal oxytocin for cocaine dependent individuals receiving methadone maintenance treatment for opioid use disorder. Addiction Research & Theory. 2016. In Press.

  28. Mitchell JM, Arcuni PA, Weinstein D, Woolley JD. Intranasal Oxytocin Selectively Modulates Social Perception, Craving, and Approach Behavior in Subjects with Alcohol Use Disorder. Journal of Addiction Medicine. 2016 May-Jun;10(3):182-189. [link]

  29.  Woolley JD, Arcuni P, Stauffer CS, Carson D, Fulford D, Batki S, Vinogradov S. “The effects and efficacy of intranasal oxytocin in opioid-dependent individuals and healthy control subjects: a pilot study”.Psychopharmacology. 2015 Apr; 1-10. In Press.

  30. Quintana DS, Woolley JD. Intranasal oxytocin mechanisms can be better understood but its effects on social cognition and behavior are not to be sniffed at. Biological Psychiatry. 2015 Jun 21. [pdf]

  31. Woolley J, Strobl EV, Sturm VE, Shany-Ur T, Poorzand P, Grossman S, Nguyen L, Eckart JA, Levenson RW, Seeley WW, Miller BL, Rankin, KP. Impaired recognition and regulation of disgust is associated with distinct but partially overlapping patterns of decreased gray matter volume in the ventroanterior insula. Biological Psychiatry. 2015 [in-press]. 

  32. Woolley JD, Lam O, Chuang B, Ford JM, Mathalon DH, Vinogradov S. Oxytocin administration selectively improves olfactory detection thresholds for lyral in patients with schizophrenia. Psychoneuroendocrinology. 2015 Mar; 53:217-222. [pdf]

  33. Stauffer CS, Woolley JD. Can we bottle psychosocial treatments for addiction? The role of oxytocin. J Clin Psychiatry 2014 Sep; 75(9): 1028-9. PMID: 25295428

  34. Woolley JDChuang B, Lam O, Lai W, O’Donovan A, Rankin, KL, Mathalon D, Vinogradov S. Oxytocin administration enhances controlled social cognition in patients with schizophrenia. Psychoneuroendocrinology. 2014 Sep; 47:116-125. [pdf]

  35. Daubenmier, J, Lustig,  R, Hecht, F, Kristeller, J, Woolley, JD, Adam, Tanja, Dallman, Mary, Epel, Elissa. A New Biomarker of Hedonic Eating? A Preliminary Investigation of Cortisol and Nausea Responses to Acute Opioid Blockade. Appetite. 2014 Mar; 74:92-100. [pdf]

  36. Woolley JD, Khan BK, Natesan A, Karydas A, Dallman M, Havel P, Miller BL, Rankin KP. Satiety-Related Hormonal Dysregulation in Patients with Behavioral Variant Frontotemporal Dementia. Neurology. 2014 Feb 11; 82(6):512-20. [pdf]

  37. Khan BK, Woolley JD., Chao S, See T, Karydas AM, Miller BL, Rankin KP. Schizophrenia or Neurodegenerative Disease Prodrome? Outcome of a First Psychotic Episode in a 35-Year-Old Woman. Psychosomatics. 2012 Jan 25. [pdf]

  38. Woolley JD., Strobl, EV, Shelly, WB, Miller, BL, Wolkowitz, OM, Mellon, SH Rankin, KP. BDNF serum concentrations show no relationship with diagnostic group or medication status in neurodegenerative disease. Curr. Alzheimer Res. 2011 May 24. [pdf]

  39. Woolley JD., Khan, BK, Murthy, NM, Miller, BL, Rankin, KP. Rates of and risk factors for psychiatric misdiagnosis in patients with early neurodegenerative disease. J. Clin. Psychiatry. 2011 Feb;72(2):126-33. [pdf]

  40. Woolley JD., Douglas, VC, Cree, BAC. Neuromyelitis optica and primary polydipsia: a case report. Gen Hosp Psychiatry. 2010 Nov-Dec;32(6):648.e5-8. [pdf]

  41. Woolley JD., Wilson, MR, Hung, E, Gorno-Tempini, ML, Miller, BL, Shim, J. Frontotemporal dementia and mania. Am. J. Psychiatry. 2007. 164(12): p.1811-6. [pdf]

  42. Woolley JD., Gorno-Tempini, ML, Seeley, WW, Rankin, K, Lee, SS, Matthews, BR, Miller, BL. Binge eating is associated with right orbitofrontal-insular-striatal atrophy in frontotemporal dementia. Neurology, 2007. 69(14): p.1424-33. [pdf]

  43. Woolley JD., Lee BS, Kim B, and Fields HL. Opposing effects of intra-nucleus accumbens mu and kappa opioid agonists on sensory specific satiety. Neuroscience, 2007. 146(4): p.1445-52. [pdf]

  44. Woolley JD., Lee BS, Taha SA, and Fields HL. Nucleus accumbens opioid signaling conditions short-term flavor preferences. Neuroscience, 2007. 146(1): p.19-30. [pdf]

  45. Woolley JD., Lee BS, and Fields HL. Nucleus accumbens opioids regulate flavor-based preferences in food consumption. Neuroscience, 2006. 17(143(1)): p.309-17. [pdf]

  46. Taha SA, Norsted E, Lee LS, Lang PD, Lee BS, Woolley JD., and Fields HL. Endogenous opioids encode relative taste preference. Eur J Neurosci, 2006. 24(4): p. 1220-6. [pdf]

  47. Woolley JD., Gorno-Tempini ML, Werner K, Rankin KP, Ekman P, Levenson RW, and Miller BL. The autonomic and behavioral profile of emotional dysregulation. Neurology, 2004. 63(9): p.1740-3. [pdf]

  48. Gorno-Tempini ML, Rankin KP, Woolley JD, Rosen HJ, Phengrasamy L, Miller BL. Cognitive and behavioral profile in a case of right anterior temporal lobe neurodegeneration. Cortex. 2004 Sep-Dec;40(4-5): p.631-44. [pdf]

  49. Woolley JD. Buccofacial apraxia and the expression of emotion. Ann N Y Acad Sci. 2003 Dec;1000: p.395-401. [pdf]

  50. Woolley JD., Svensson* E, Wikström M, and Grillner S. Endogenous dopaminergic modulation of the lamprey spinal locomotor network. Brain Res. 2003. Apr 25;970(1-2): p.1-8. [pdf]

  51. Woolley JD. The functional morphology of the avian flight muscle M. Coracobrachialis posterior. J Exp Biol. 2000. 203(11): p.1767-76. [pdf]